Molecular Action of Tamoxifen in the Ovaries of Rats with Mammary Neoplasia

• Published in: International journal of molecular sciences Vol. 24; no. 21; p. 15767
• Main Authors: Nynca, Anna, Swigonska, Sylwia, Molcan, Tomasz, Petroff, Brian K, Ciereszko, Renata E
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.11.2023
• Subjects: Apoptosis; Breast cancer; Cancer; Chemotherapy; Cysts; Estrogen; Estrogens; Follicles; Genes; Genomes; Metabolism; Oncology, Experimental; Ovaries; ovary; Proteins; proteome; RNA; RNA sequencing; Steroids; Tamoxifen; transcriptome; tumor-bearing rats; Poland
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms242115767

Tamoxifen (TAM) is a drug commonly used in patients with breast cancer. The anticancer effect of TAM occurs via its ability to antagonize estrogen-dependent growth of mammary epithelial cells. Previously, we demonstrated that TAM prevented the chemotherapy-induced loss of ovarian follicular reserves in both cancer-free rats and rats with cancer. Such follicular loss is a main cause of infertility in young women treated for cancer. The current study was undertaken to discover the molecules and intracellular pathways involved in the action of TAM in the ovaries of rats with mammary tumors. To meet this goal we used transcriptomic (RNA-Seq) and proteomic (2D-DIGE/MS) approaches. TAM inhibited the expression of genes and lncRNAs involved in ovarian steroidogenesis. Moreover, TAM altered the expression of genes related to primordial follicle activation or arrest. In addition, proteomic screening indicated the importance of basic metabolic processes in the ovarian actions of TAM. Although simple extrapolation of these data to humans is not possible, the results of this study emphasize the need to explore the ability of TAM to affect ovarian function in women undergoing cancer treatment.